# An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

> **NCT02823145** · PHASE3 · COMPLETED · sponsor: **Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.** · enrollment: 375 (actual)

## Conditions studied

- Dravet Syndrome

## Interventions

- **DRUG:** ZX008 (Fenfluramine Hydrochloride)

## Key facts

- **NCT ID:** NCT02823145
- **Lead sponsor:** Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-08
- **Primary completion:** 2023-01-27
- **Final completion:** 2023-01-27
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823145, "An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02823145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*